{ "meta": { "data_length": 1, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A858", "status": "success", "status_code": 200, "timestamp_elapsed": 0.004208, "timestamp_received": "2026-09-25T01:17:19.121990+00:00Z", "timestamp_returned": "2026-09-25T01:17:19.126198+00:00Z", "trace_id": "1f76b6b4-a470-43bd-9f80-9a87dcfd12ca" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:hernexeos:0:0", "type": "Statement", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).", "contributions": [ { "id": "ctrb:fda:2026-02-26:0", "type": "Contribution", "description": "The clinical eligibility criteria for this indication were expanded on 2026-02-26 by removing the prior therapy restriction.", "date": "2026-02-26", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } }, { "id": "ctrb:vanallenlab:2025-09-03:1", "type": "Contribution", "description": "The US FDA approved zongertinib for the treatment of zongertinib for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations.", "date": "2025-09-03", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2025-08-08:0", "type": "Contribution", "description": "Indication received accelerated approval.", "date": "2025-08-08", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:hernexeos", "type": "Document", "documentType": "Regulatory approval", "name": "Hernexeos (zongertinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Boehringer Ingelheim Pharmaceuticals, Inc. Hernexeos (zongertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219042s001lbl.pdf. Revised February 2026. Accessed March 2, 2026.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219042s001lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219042" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Boehringer Ingelheim Pharmaceuticals, Inc.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Hernexeos", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "sunvozertinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2025-08-08", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 219042, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2026-02-26", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:858", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C135017", "conceptType": "Disease", "name": "Lung Non-Squamous Non-Small Cell Carcinoma", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C135017", "code": "C135017", "name": "Lung Non-Squamous Non-Small Cell Carcinoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C135017" ] } }, "objectTherapeutic": { "id": "tx:ncit:C199022", "conceptType": "Therapy", "name": "Zongertinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2721604", "code": "2721604", "name": "zongertinib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2721604" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:37353943", "code": "37353943", "name": "zongertinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/37353943" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "HER2 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C199022", "code": "C199022", "name": "Zongertinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C199022" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:173", "present": true, "subject": { "id": "bmkr:173", "type": "CategoricalVariant", "name": "ERBB2 TKD activating variants", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.gpkyq48rchUXfr_dVmt7BXbjBYofmUvG", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence within refseq:NP_004439.2, the protein product of the MANE Select coding transcript for ERBB2 (refseq:NM_004448.4), corresponding to the tyrosine kinase domain (residues 712-990; NCBI CDD PTKc_HER2, cd05109).", "digest": "gpkyq48rchUXfr_dVmt7BXbjBYofmUvG", "sequenceReference": { "id": "ga4gh:SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m", "type": "SequenceReference", "name": "NP_004439.2", "aliases": [ "ensembl:ENSP00000269571.4", "ga4gh:SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m", "refseq:NP_004439.2" ], "description": "The protein product of the MANE Select coding transcript for ERBB2 (refseq:NM_004448.4), corresponding to the Refseq protein accession NP_004439.2.", "moleculeType": "protein", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m", "residueAlphabet": "aa" }, "start": 711, "end": 990, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:3430", "conceptType": "Gene", "name": "ERBB2", "primaryCoding": { "id": "coding:hgnc:3430", "code": "HGNC:3430", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000141736", "code": "ENSG00000141736", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000141736" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:2064", "code": "2064", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/2064" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004448.4", "code": "NM_004448.4", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4" ] } } ] } }, { "type": "FunctionConstraint", "functionConsequence": { "id": "func:so:0002053", "name": "Gain-of-function", "primaryCoding": { "id": "coding:so:0002053", "code": "SO:0002053", "name": "gain_of_function_variant", "system": "https://www.ebi.ac.uk/ols4/ontologies/so", "iris": [ "https://www.ebi.ac.uk/ols4/ontologies/so/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FSO_0002053" ] } } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "17" }, { "name": "start_position", "value": null }, { "name": "end_position", "value": null }, { "name": "reference_allele", "value": null }, { "name": "alternate_allele", "value": null }, { "name": "cdna_change", "value": null }, { "name": "protein_change", "value": null }, { "name": "variant_annotation", "value": null }, { "name": "exon", "value": null }, { "name": "rsid", "value": null }, { "name": "hgvsg", "value": null }, { "name": "hgvsc", "value": null }, { "name": "requires_oncogenic", "value": true } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:hernexeos:0", "type": "Indication", "description": "HERNEXEOS is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).", "contributions": [ { "id": "ctrb:fda:2026-02-26:0", "type": "Contribution", "description": "The clinical eligibility criteria for this indication were expanded on 2026-02-26 by removing the prior therapy restriction.", "date": "2026-02-26", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } }, { "id": "ctrb:vanallenlab:2025-09-03:1", "type": "Contribution", "description": "The US FDA approved zongertinib for the treatment of zongertinib for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations.", "date": "2025-09-03", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2025-08-08:0", "type": "Contribution", "description": "Indication received accelerated approval.", "date": "2025-08-08", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:hernexeos", "type": "Document", "documentType": "Regulatory approval", "name": "Hernexeos (zongertinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Boehringer Ingelheim Pharmaceuticals, Inc. Hernexeos (zongertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219042s001lbl.pdf. Revised February 2026. Accessed March 2, 2026.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219042s001lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219042" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Boehringer Ingelheim Pharmaceuticals, Inc.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Hernexeos", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "sunvozertinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2025-08-08", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 219042, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2026-02-26", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Accelerated", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }